|Values are valid only on day of printing.|
Updated: October 2013
Published: May 2013
Mayo Medical Laboratories is pleased to announce the availability of our:
This panel uses next generation sequencing (NGS), array comparative genomic hybridization (aCGH), and other technologies to evaluate for germline mutations in 17 genes known to be associated with an increased risk for colon cancer development.
Problems playing the video? View it on Mayo Clinic's YouTube Channel.
The Hereditary Colon Cancer Multi-Gene Panel was developed in collaboration with the Mayo Clinic Center for Individualized Medicine, a team that integrates genomic, molecular and clinical science into personalized care for each Mayo patient.
|APC||Familial Adenomatous Polyposis|
|MYH / MutYH||MYH-associated Polyposis|
|SCG5 / GREM1||Hereditary Mixed Polyposis syndrome|
|SMAD4||Juvenile Polyposis syndrome|
|BMPR1A||Juvenile Polyposis syndrome|
|PTEN||PTEN Hamartoma Tumor syndrome (Cowden syndrome)|
|CDH1||Hereditary Diffuse Gastric Cancer|
|AXIN2||Oligodontia-Colorectal Cancer syndrome|
*CHEK2 and MLH3, are not associated with a known hereditary cancer syndrome defined by a distinct spectrum of tumors. However, literature suggests that mutations in these genes may confer an increased risk for colon cancer and therefore are predicted to contribute to cancer risk in patients and families.